Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.

By N. Ferrara, Kenneth J. Hillan, W. Novotny. Biochemical and Biophysical Research Communications - BBRC, 2005

1,036 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/76ad228abe5bec7951c666c940d1b579c4d640f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Roskoski

In Molecular Biology

1. R. Roskoski
2. B. Hempstead

In Oncology

1. R. Roskoski

Citations in the corpus

• In vitro microvessels for the study of angiogenesis and thrombosis (2012, methodology): “As our platform matures, we anticipate that μVNs can be used to test drugs and drug-delivery strategies that target microvascular function (for example, angiogenesis (47) and hypertension)”
• Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “Bevacizumab is less effective as a single agent (monotherpy) when used in the treatment of human cancers when ompared with human tumor xenografts in athymic nude ice [8,267].”